UPDATE: Stifel Reiterates on Aratana Therapeutics Following Meetings with Multiple Companies

In a report published Monday, Stifel analyst Jonathan Block reiterated a Buy rating on Aratana Therapeutics (NASDAQ: PETX ), but lowered the price target from $33.00 to $30.00. In the report, Stifel noted, “Over the past couple of weeks we met with several companies in the burgeoning pet therapeutics space.